BMY Bristol-Myers Squibb Co. Compare

barrons

Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion

reuters

Bristol Myers to buy RayzeBio for about $4.1 billion

insidermonkey

15 Undervalued Defensive Stocks For 2024

yahoo

Bristol-Myers Squibb Will Pay A Larger Dividend Than Last Year At $0.60

investopedia

S&P 500 Gains and Losses Today: Nike Warns of Soft Sales and Plans Spending Cuts

abcnews.go

Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio

investopedia

Midday Movers: Karuna Jumps on Deal With Bristol Myers Squibb, Nike Falls on Sales Outlook

investopedia

Bristol Myers Squibb Boosts Its Neuroscience Reach With $14 Billion Karuna Deal

investopedia

5 Things to Know Before The Stock Market Opens

barrons

Bristol Myers to Buys Karuna Therapeutics in $14 Billion Pharma Deal

duckduckgo

Bristol Myers Squibb to Present at J.P. Morgan’s 42nd Annual Healthcare Conference

reuters

Bristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 billion

zacks

Bristol Myers Squibb Rises But Trails Market: What Investors Should Know

morningstar

Bristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference

zacks

5 Stocks to Watch on Their Recent Dividend Hike

insidermonkey

10 Highest Dividend Stocks on Cash App

wsj

Bristol Myers Squibb to Discontinue Metastatic Colorectal Cancer Trial

reuters

UPDATE 2-Bristol Myers to discontinue trial for colorectal cancer treatment

businesswire

Bristol Myers Squibb Provides Update on RELATIVITY-123 Trial Evaluating the Fixed-Dose Combination of Nivolumab and Relatlimab in Patients with Previously Treated Metastatic Microsatellite Stable Colorectal Cancer

businesswire

Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024

insidermonkey

20 Countries With Highest Rate Of Breast Cancer In The World

insidermonkey

30 Largest Pharmaceutical Companies in the World

businesswire

Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023

businesswire

Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs

morningstar

Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3

reuters

UPDATE 1-Bristol Myers to pay $800 mln up front to Chinese drugmaker to develop cancer drug

businesswire

Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia

fool

This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks

insidermonkey

12 Healthcare Stocks Billionaires Like the Most

morningstar

Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023

insidermonkey

12 Biggest Financial Scandals in US History

morningstar

Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo Plus Yervoy Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...

morningstar

Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization

businesswire

Bristol Myers Squibb Announces Dividend Increase

insidermonkey

Hedge Funds are Betting on These 14 Sliding Stocks

insidermonkey

15 Best Safe Dividend Stocks For 2024

businesswire

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic...

barrons

Bristol Myers Squibb CEO Chris Boerner Buys Up Stock

barrons

Bristol Myers Stock Is Slumping. One Director Bought Up Shares.